Sugi Predict

Sugi Predict / Compounds / SCHEMBL531838

SCHEMBL531838

SCHEMBL531838

O=Cc1ccc2c(c1)NC(=O)CO2

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MMP12 P39900 1/20 0.61
▸ NR3C2 P08235 5/20 0.58
▸ PARP1 P09874 3/20 0.56
▸ ALDH1A1 P00352 7/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ MAPT P10636 4/20 0.52
▸ PKM P14618 1/20 0.52
▸ LMNA P02545 1/20 0.51
▸ GAA P10253 2/20 0.48
▸ HSD17B10 Q99714 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ TRPV1 Q8NER1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13932054 0.90 NR3C2 (0.59) MMP12NR3C2PARP1ALDH1A1KMT2A
SCHEMBL4267779 0.90 NR3C2 (0.59) MMP12NR3C2PARP1ALDH1A1KMT2A
SCHEMBL3027487 0.88 CYP11B1 (0.50) MMP12NR3C2PARP1ALDH1A1KMT2A
SCHEMBL4265388 0.85 MMP12 (0.59) MMP12NR3C2PARP1ALDH1A1KMT2A
SCHEMBL4421255 0.85 MMP12 (0.64) MMP12NR3C2PARP1ALDH1A1KMT2A
SCHEMBL27731422 0.83 NR3C2 (0.65) MMP12NR3C2PARP1ALDH1A1KMT2A
SCHEMBL4267374 0.81 ALDH1A1 (0.67) MMP12NR3C2PARP1ALDH1A1KMT2A
SCHEMBL13932080 0.81 ALDH1A1 (0.67) MMP12NR3C2PARP1ALDH1A1KMT2A
SCHEMBL23831019 0.80 MMP12 (0.54) MMP12NR3C2PARP1ALDH1A1KMT2A
SCHEMBL4263120 0.80 NR3C2 (0.62) MMP12NR3C2PARP1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2025-10-23 — — US disclosed
US-12312359-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2025-05-27 — — US disclosed
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 — — EP disclosed
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 — — CN disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 — — US disclosed
WO-2024006881-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-04 — — WO disclosed
WO-2023201012-A1 IKZF2 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-19 — — WO disclosed
WO-2023201012-A1 IKZF2 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-19 — — WO disclosed
US-20230174541-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, LLC 2023-06-08 — — US disclosed
US-11603349-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD (AU) 2023-03-14 — — US disclosed
EP-1359908-A1 QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2003-11-12 — — EP disclosed
WO-2003087098-A1 NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 — — WO disclosed
WO-2003068772-A1 HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY GLAXO GROUP LIMITED (GB) 2003-08-21 — — WO disclosed
EP-1330460-A2 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM PLC (GB) 2003-07-30 — — EP disclosed
EP-0906294-B1 BENZOXAZINONE DOPAMINE D4 RECEPTOR ANTAGONISTS WARNER LAMBERT CO (US) 2003-01-29 — — EP disclosed
WO-2002056882-A1 QUINOLINES AND NITROGENATED DERIVAIVE THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-25 — — WO disclosed
WO-2002034754-A2 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM P.L.C. (GB) 2002-05-02 — — WO disclosed
US-6177422-B1 ANTIPSYCHOTIC AGENT WITH REDUCED SIDE EFFECTS WARNER-LAMBERT COMPANY 2001-01-23 — — US disclosed
EP-0906294-A1 BENZOXAZINONE DOPAMINE D4 RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1999-04-07 — — EP disclosed
WO-1997045419-A1 BENZOXAZINONE DOPAMINE D4 RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-12-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174541-A1 INHIBITORS OF THE MENIN-MLL INTERACTION MLLT1, MEN1, MLLT3 MMP12 1834/4885NR3C2 2959/4885PARP1 609/4885
US-11603349-B2 Anti-fibrotic compounds TGFB1, SMAD3, TGFB2 MMP12 23/4885NR3C2 615/4885PARP1 2271/4885
US-12312359-B2 Inhibitors of the menin-MLL interaction MLLT1, MEN1, MLLT3 MMP12 1834/4885NR3C2 2959/4885PARP1 609/4885
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 MMP12 2610/4885NR3C2 3283/4885PARP1 411/4885
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION MLLT1, MEN1, MLLT3 MMP12 1834/4885NR3C2 2959/4885PARP1 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.